Mode
Text Size
Log in / Sign up
N/A N=513 Randomized Triple-blind Prevention

Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE

Respiratory Failure

Enrolled (actual)
513
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Microaspiration as Measured by Tracheal Amylase — 13,086; 15,298 U/L — p=0.432

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Enhanced oropharyngeal suction (Other); Usual Care (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Central Florida
Primary completion
Aug 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Microaspiration as Measured by Tracheal Amylase
13,086; 15,298 0.432
PRIMARY
Microaspiration as Measured by Percentage of Tracheal Specimens Positive for Amylase Per Participant
75.2; 78.4 0.684
SECONDARY
Ventilator-Associated Condition (VAC) Rate
31; 32 0.858
SECONDARY
Time to VAC
4.94; 5.72

Summary

Insertion of a breathing tube to enable treatment with mechanical ventilation (respirator) is often associated with complications, such as infection and lung injury. Leakage of secretions around the breathing tube (microaspiration) is a major factor leading to complications. The investigators propose that a standardized, enhanced oral suction protocol will be effective in reducing microaspiration and harms associated with mechanical ventilation. The investigators hypothesize that those randomized to the enhanced oral suction protocol will have less microaspiration and other ventilator-associated conditions than those in the usual care, standard suction group.

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • orally intubated with endotracheal tube and treated with mechanical ventilation
  • 24 hours or less since intubation
  • expected to be intubated for at least 36 hours after enrollment

Exclusion Criteria

  • documented aspiration at time of intubation
  • intubation to treat known aspiration
  • treatment with rescue mechanical ventilation therapies (oscillator)
  • re-intubation
  • contraindications to receiving the intervention (e.g., oral injuries)
  • history of lung or head/neck cancers that may produce amylase in the lungs
  • history of disease that affects saliva production (e.g., Sjögren's syndrome)
  • prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02284178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search